Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning

Abstract

Prostate cancer is known to have a variable response to androgen receptor signalling inhibitors. Here, the authors use machine learning to predict response to therapy from genomic, transcriptomic and clinical data.